AEON Biopharma, Inc. (AEON)
| Market Cap | 21.57M +387.6% |
| Revenue (ttm) | n/a |
| Net Income | -39.22M |
| EPS | -3.95 |
| Shares Out | 26.31M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 162,111 |
| Open | 0.8691 |
| Previous Close | 0.8800 |
| Day's Range | 0.8130 - 0.8770 |
| 52-Week Range | 0.4601 - 1.4500 |
| Beta | 0.66 |
| Analysts | Strong Buy |
| Price Target | 7.20 (+778.05%) |
| Earnings Date | May 26, 2026 |
About AEON
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is base... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for AEON stock is "Strong Buy" and the 12-month stock price target is $7.2.
News
AEON Biopharma Sets Annual Shareholder Meeting
- Annual Shareholder Meeting to be held at 10:00 am PT on June 17, 2026 - IRVINE, Calif., April 24, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a bio...
Aeon receives additional notice related to NYSE American listing standards
AEON Biopharma (AEON) announced that on March 31, 2026, it received a notice from NYSE American indicating that, following its year-end financial results, the Company is not in compliance with…
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711
IRVINE, Calif., April 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimi...
AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards
IRVINE, Calif., April 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimi...
AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program
AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Prog
Aeon Biopharma announces FDA feedback after Type 2a meeting
Aeon Biopharma (AEON) announced feedback from the FDA following a biosimilar biological product development Type 2a meeting. During the meeting, held in January, the FDA reviewed the company’s propose...
Aeon Biopharma appoints John Bencich as CFO
Aeon Biopharma (AEON) announced the appointment of John Bencich as CFO. Most recently, he served as CEO of Achieve Life Sciences (ACHV).
Aeon Biopharma files to sell 51.29M shares of Class A common stock for holders
16:40 EST Aeon Biopharma (AEON) files to sell 51.29M shares of Class A common stock for holders
Aeon Biopharma reports BPD Type 2a meeting with FDA
Aeon confirmed that it held its scheduled BPD Type 2a meeting with FDA, in line with prior guidance. The company said it looks forward to commenting on the meeting’s substance…
AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions
- AEON confirmed that earlier today it held its BPD Type 2a Meeting with the FDA, in line with prior guidance, and is now awaiting official meeting minutes - - Separately, AEON shareholders today vote...
AEON Biopharma Announces Execution of Exchange Agreement with Daewoong
- AEON and Daewoong Pharmaceutical have executed definitive documentation to exchange $15 million of notes plus accrued interest into new equity, $1.5 million of new notes due 2030, and a cash-exercis...
Aeon Biopharma announces rescheduling of BPD Type 2a meeting with FDA
AEON Biopharma (AEON) announced the first closing of its previously announced private placement. Additionally, the Company announced that the U.S. Food and Drug Administration has proposed a new date ...
AEON Biopharma Announces First Closing of PIPE Investment and Provides Update on FDA Type 2a Meeting Scheduling
- First closing of PIPE resulted in ~$1.79M in proceeds - - FDA BPD Type 2a meeting now scheduled for January 21, 2026 - IRVINE, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” ...
Aeon Biopharma reports Q3 EPS (39c) vs ($11.24) last year
“The foundation of AEON‘s progress lies in our science and is underscored by years of market validation”, said Rob Bancroft, AEON’s President and Chief Executive Officer. “Our recently released analyt...
AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth
– FDA Type 2a meeting scheduled for November 19, 2025, to review AEON's analytical development plan and initial data – – Positive biosimilarity data for ABP-450 confirming identical amino-acid sequenc...
AEON Biopharma Announces Fundraise Totaling Up to ~$22 Million through Private Placement and Proposed Exchange of Daewoong Convertible Notes
- Combined transactions will strengthen balance sheet and reduce outstanding debt by more than 90% - - $6 million PIPE financing with potential for over $7 million of additional capital via cash-exerc...
Aeon Biopharma announces FDA BPD Type 2a meeting for ABP-450
AEON Biopharma (AEON) announced that the U.S. Food and Drug Administration has scheduled a Biosimilar Biological Product Development Type 2a meeting for ABP-450 on November 19, 2025, in line with…
AEON Biopharma Announces FDA BPD Type 2a Meeting for ABP-450 on November 19
- Meeting date aligns with prior guidance - - FDA to review AEON's analytical development plan and initial data - IRVINE, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the ...
AEON Biopharma Reports Second Quarter 2025 Financial Results and Provides Corporate Update
– Multiple near-term potential milestones, including anticipated completion of primary structure analysis and select functional analyses in 3Q'25 – – Type 2a meeting with the FDA anticipated in 4Q'25–...
AEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025
IRVINE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex...
AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update
– Continue to conduct analytical studies to prepare for a potential Biosimilar Biological Product Development (“BPD”) Type 2a meeting with the FDA in the second half of 2025 –
AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance
IRVINE, Calif., April 25, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin compl...
Aeon Biopharma appoints Rob Bancroft as CEO
Aeon Biopharma (AEON) announced the appointment of Rob Bancroft as president and CEO, effective April 29. Bancroft will also join Aeon’s board of directors. Bancroft brings over 25 years of…
AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer
– Former CEO, Marc Forth, to remain as a member of the Company's Board of Directors – – Former CEO, Marc Forth, to remain as a member of the Company's Board of Directors –
AEON Biopharma Announces CEO Transition
– Marc Forth Steps Down as President and CEO to Pursue Another Opportunity; will remain on the Board of Directors – – Jost Fischer, Chairman of AEON, will assume the role of interim CEO – IRVINE, Cali...